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SUMMARY 
Narcolepsy type 1 is a neurological disorder characterized by a unique syndrome, including 
the pathognomonic symptom of cataplexy. The diagnosis can be convincingly confirmed by 
objective measures such as typical findings in the multiple sleep latency test, reduced or 
undetectable levels of orexin (hypocretin) in the cerebrospinal fluid (CSF), and a 95-100% 
linkage to a specific HLA haplotype. Nevertheless, the mean time that elapses from symptom 
onset to the correct diagnosis ranges between 10-20y, and the causes and correlates of this 
delay are poorly understood. We assessed diagnostic delay in on 52 well-defined patients 
with narcolepsy type 1, evaluating clinical, electrophysiological and neurochemical 
parameters and the results of a 41-item questionnaire developed to obtain the patients’ 
perspective on various aspects of the diagnostic process. Mean time gap between disease 
onset and first medical consultation was 3.2±5.1y; the mean diagnostic delay was 8.9±11.0y. 
Prior to correct diagnosis, patients received a wide variety of misdiagnoses. The self-ratings 
of the patients revealed that the undiagnosed symptoms caused high levels of anxiety and 
unjustified criticism by family, friends and employers. Multiple regression analysis identified 
higher CSF orexin levels (β=0.311, p=0.01), and longer interval between onset of excessive 
daytime sleepiness and cataplexy (β=0.368, p=0.002) as independent associates of longer 
diagnostic delay. The diagnostic delay decreased over the last decades (β=-0.672, p<0.001). 
In conclusion, delayed diagnosis of narcolepsy type 1 is very common, associated with many 
adverse consequences, and requires educational efforts to improve awareness on 
narcolepsy among health-care providers and the general population. 
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INTRODUCTION 
 Narcolepsy type 1 is a neurological disorder characterized by excessive daytime 
sleepiness and cataplexy (Scammell, 2015). The narcoleptic pentad is complete, if the 
patient also presents hypnagogic or hypnopompic hallucinations, sleep paralysis and 
fragmented night-time sleep. Cataplexy, the remarkable sudden loss of muscle tone with 
emotions, is highly specific to narcolepsy type 1, and when familiar with this symptom, 
clinicians can easily anticipate make the correct diagnosis. The presence of typical findings 
on the multiple sleep latency test (MSLT), reduced or undetectable levels of orexin 
(hypocretin) in the cerebrospinal fluid (CSF), and a positive HLA-DQB1*06:02 haplotype 
usually allow an unequivocal diagnosis. In this regard, narcolepsy type 1 clearly differs from 
narcolepsy type 2, which remains a diagnostic challenge, as the symptoms are much less 
specific (no cataplexy) and the biomarkers, including CSF orexin levels and HLA haplotype, 
are often not present (Baumann et al., 2014).  
 Despite these reliable diagnostic criteria, the correct recognition of narcolepsy type 1 
often occurs with a lengthy delay (Thorpy and Krieger, 2014). According to the few studies 
on this topic, the mean latency between disease onset and correct diagnosis varies between 
8.7 years (Ingravallo et al., 2012), 12 years (Frauscher et al., 2013), 15 years (Morrish et al., 
2004), 16 years (Broughton et al., 1997), and 19.3 years (Thorpy et al., 1999). Up to half of 
all affected patients may actually never learn that they are suffering from narcolepsy 
(Scammell, 2015). 
The failure of a correct and timely diagnosis is clearly a major issue, as narcolepsy is 
associated with deleterious life effects and high socio-economic burden (Black et al., 2014; 
Broughton et al., 1981; Ingravallo et al., 2012), and because efficacious treatment options 
are now increasingly available. The reasons contributing to this long interval between 
disease onset and accurate diagnosis are poorly understood, and the above-mentioned 
studies have various methodological limitations, such as inclusion of both type 1 and 2 
narcolepsy patients, lack of diagnostic confirmation by objective measures and reliance on 
medical records only. 
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The present single-center study aims at characterizing the diagnostic delay in well-
defined patients with narcolepsy type 1, based on detailed clinical, electrophysiological and 
neurochemical parameters on the one hand and by using a 41-item questionnaire to obtain 
the patients’ perspective on this issue on the other hand. 
 
METHODS  
This study was conducted at the Department of Neurology, University Hospital Zurich, 
Switzerland, between October 2014 and January 2016. The study protocol was approved by 
the Ethics Committee of the Canton of Zurich, specialized subcommittee for Psychiatry, 
Neurology, Neurosurgery (project number 2015-0165), and written informed consent was 
obtained by all patients at study inclusion. 
Participants 
 We retrospectively identified 67 patients with narcolepsy type 1 with regular 
follow-ups at our sleep clinic since 2003. The diagnostic criteria for narcolepsy type 1 of the 
revised 3rd edition of the International Classification of Sleep Disorders (ICSD-3) were fulfilled 
in each patient. They all had persuasive cataplectic attacks. The diagnosis was confirmed by 
typical MSLT findings in 44 patients and reduced CSF orexin levels in 39 patients. HLA-
genotyping was available in 42 patients. Two patients had to be excluded because they do 
not speak German, one patient had advanced Alzheimer’s disease, one declined study 
participation, four patients were lost during follow-up, and seven patients did not return the 
questionnaire. Eventually, we included 52 patients (78%) in the study. 
 By performing a thorough chart review of these 52 patients, we retrieved data 
regarding year of onset of excessive daytime sleepiness and cataplexy, year of diagnosis 
and the respective ages of the patients. Demographical and clinical information included age, 
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sex, highest educational degree, current work capacity, and body-mass index. In-house 
MSLT data were available in 44 patients, and all had a mean sleep latency <8 minutes and 
≥2 sleep onset REM periods. Measurement of CSF orexin levels was performed in 39 
patients, using a radioimmunoassay (RIA) as previously described (Baumann et al., 2004); 
all patients had reduced CSF orexin levels. HLA-DQB1*06:02 was determined in 42 patients. 
Questionnaire 
Purely for the purpose of this study, we developed a questionnaire with 41 items 
regarding various aspects of the diagnostic process, the meaning of a correct diagnosis and 
the circumstances of delayed diagnosis. Most items describe situations or contain claims and 
the patients had to indicate on a visual analogue scale whether they agree or disagree, with 
0 meaning maximal disagreement and 10 maximal agreement. Other items are questions 
and the patients had a choice between 3-5 different answers, with the possibility to mark 
multiple statements or to make additional comments. Seven question pairs inquired about 
disease-related consequences, comparing the situations before diagnosis and at the moment 
of study conduction.  
Statistical analysis 
Statistical analyses were performed using SPSS (version 22). Group data were 
described by means and standard deviations. For normally distributed data, we used 
Student's t-test, otherwise Mann–Whitney U-test was applied. Chi-square test was used for 
nominal data. We calculated Pearson's r for correlation analysis. We applied the paired 
samples t-test to compare the patients’ ratings of their situations before and after diagnosis. 
To identify predictors of longer diagnostic delay, we performed stepwise multiple linear 
regression analysis with the following independent variables: year of disease onset, latency 
between onset of sleepiness and cataplexy, CSF orexin level, latency between symptom 
onset and first medical consultation, body mass index, Epworth Sleepiness Scale at 
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diagnosis, mean sleep latency on MSLT, age at diagnosis, education, number of symptoms 
at disease onset. Significance was accepted at p<0.05. 
 
RESULTS 
Table 1 provides a detailed overview on the patients’ characteristics. In 37 patients 
(71%), the first manifestation of excessive daytime sleepiness and cataplexy occurred in the 
same year, but in the remaining 15 patients (29%) cataplexy occurred 3.8±4.3y later (range: 
1-17y). 
There was a time gap between disease onset and first medical consultation of 
3.2±5.1y. This delay in seeking medical advice correlated with the overall diagnostic delay 
(r=0.576, p<0.001). Longer time gap to first medical consultation was associated with older 
age at diagnosis (r=0.342, p=0.02). Educational degree did not influence the time to first 
medical consultation (r=-0.215, p=0.17).  
The diagnostic delay varied between 1 month and 43 years, with a mean of 8.9±11.0y 
and a median of 5.5y (Fig. 1A). Multiple linear regression analysis revealed higher CSF 
orexin levels (β=0.311, p=0.01) and longer interval between onset of excessive daytime 
sleepiness and cataplexy (β=0.368, p=0.002) as independent associates of a longer 
diagnostic delay. In addition, patients with longer diagnostic delay had a higher body mass 
index at the moment of diagnosis (r=0.274, p=0.05). 
Over the last 50 years, the diagnostic delay (r=-0.737, p<0.001) and the latency from 
first symptom manifestation to first medical consultation (r=-0.568, p<0.001) became shorter 
(Fig. 1B+C). Multiple linear regression analysis identified earlier year of disease onset as 
strongest predictor of longer diagnostic delay (β=-0.672, p<0.001).  
 Patients rated the overall burden caused by the undiagnosed disease as 7.4±2.4 on 
the visual analogue scale. At the moment of study conduction, i.e. after diagnosis and 
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established treatment, the disease burden was reduced to 4.6±2.7 (p<0.001). As shown in 
Fig. 2, the undiagnosed disease had many adverse consequences in patients’ life, with 
improvement of all aspects when narcolepsy was recognized as the responsible disorder. At 
disease onset, only 15 patients (29%) believed that the various narcoleptic symptoms 
belonged to one single disease; the majority did not spontaneously think about this question 
(60%) or thought that any symptom represents a different disease (11%). Table 2 shows the 
various aspects related to the delayed recognition of the correct diagnosis. Most patients 
received one or more misdiagnoses (Fig. 3), together with many inappropriate diagnostic 
procedures and treatments. 
 The patients believe that the long interval that elapsed from disease onset to correct 
diagnosis has compromised many aspects of their life (Fig. 4). They emphasize that, in 
hindsight, many disadvantages would seem avoidable, if the correct diagnosis had been 
recognized earlier. When asked about the causes of the diagnostic delay, 64% of the 
patients blamed the treating physicians for insufficient knowledge on narcolepsy, 24% 
blamed themselves for not having sought medical advice earlier, and 12% regarded both 
delayed medical consultation and insufficient symptom recognition by their treating 
physicians as the main cause. Accordingly, a majority of the patients are convinced that a 
rapid diagnosis of narcolepsy requires improved knowledge among both physicians (69%) 
and the general population (77%). 
 
DISCUSSION 
 This study confirms previous observations that there is a tendency over the last 
decades to diagnose narcolepsy with continuously shorter delay. Nevertheless, our findings 
reemphasize that people with narcolepsy are still sustaining many disadvantages because 
the correct diagnosis is recognized too late. There is considerable suffering not only because 
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efficacious treatment options are withheld, but also because patients are often criticized by 
their surroundings, who – like the physicians and the patients themselves – misinterpret their 
symptoms. 
 The diagnostic delay in our patient cohort is similar to the 8.7±8.5 years reported in 
100 Italian patients with narcolepsy type 1 (Ingravallo et al., 2012), but shorter than in all 
other studies summarized in the review by Thorpy and Krieger (Thorpy and Krieger, 2014). 
Since the diagnostic delay seems to decrease in the last decades and years (Dauvilliers et 
al., 1998; Morrish et al., 2004), the shorter delay in our cohort and that of Ingravallo and 
colleagues may simply be explained because these are the most recent studies. This 
continuous reduction in diagnostic delay may reflect improved knowledge and growing 
awareness of narcolepsy among both health-care providers and the general population. 
Another similarity with the Italian study is that we only included patients with narcolepsy type 
1. The absence of cataplexy was identified as an independent predictor of longer diagnostic 
delay among 219 narcolepsy patients living in the UK (Morrish et al., 2004), and our study 
corroborates the diagnostic importance of cataplexy by identifying longer interval between 
first manifestation of excessive daytime sleepiness and cataplexy as independent predictor 
of longer diagnostic delay. Moreover, higher CSF orexin levels were independently 
associated with longer diagnostic delay, possibly because a slower or incomplete loss of 
orexin-producing neurons leads to a more insidious emergence and milder severity of 
narcoleptic symptoms, in particular of cataplexy (Sturzenegger et al., 2004; Baumann et al., 
2006; Valko et al., 2013).    
Our patients waited on average more than 3 years until they eventually decided to 
seek medical advice, and roughly one third acknowledged that this hesitation was a main 
cause of the diagnostic delay. This indicates that a considerable diagnostic delay will persist 
even with optimal knowledge and awareness about narcolepsy among health-care providers. 
On the other hand, the majority of our patients had been referred to ≥3 physicians before 
correct diagnosis, suggesting indeed that many health-care providers are not familiar enough 
with the symptoms of narcolepsy. This becomes is also apparent when considering the long 
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list of misdiagnoses, and the inappropriate diagnostic procedures and treatments the patients 
got were prescribed. The most common misdiagnoses in our patient cohort were “iron 
deficiency”, “burnout” and “psychosomatic origin”, and a similarly wide variety of mental and 
neurological misdiagnoses has been reported by others (Campbell et al., 2011; Carter et al., 
2014; Kauta and Marcus, 2012; Kryger et al., 2002; Macleod et al., 2005). Our observations 
are in keeping with the AWAKEN survey, where narcolepsy ranked lowest in the awareness 
of 1000 US adults compared to other chronic disorders, and physicians, including sleep 
medicine specialists, incompletely recognized all narcolepsy symptoms (Rosenberg and Kim, 
2014). 
Based on the questionnaire, receiving an accurate diagnosis appeared to improve 
many life aspects in our narcolepsy patients. While optimal treatment may in part account for 
this improvement, the domains with the most pronounced reductions after established 
diagnosis were anxiety and unjustified criticism by family, friends and employers. Thus, 
knowing the cause of their symptoms may alleviate the situation of narcolepsy patients 
beyond the benefits of pharmacological treatment. 
The correlation between longer diagnostic delay and higher body mass index 
additionally highlights the importance of a timely diagnosis. Researchers recognized the 
involvement of orexin in feeding behavior and body weight regulation at the very moment of 
its discovery – orexis means “appetite” in Greek – and subsequent studies described 
increased body mass index and disturbed glucose and fat metabolism in patients with 
narcolepsy (Donjacour et al., 2014; Schuld et al., 2000). Moreover, treatment with sodium 
oxybate, currently the most commonly prescribed drug for narcolepsy patients in many sleep 
clinics, has been associated with weight loss (Husain et al., 2009), possibly because it 
stimulates lipolysis (Donjacour et al., 2014). Thus, early diagnosis and, hence, early 
treatment may reduce the patients’ risk of additional weight gain due to orexin deficiency. 
 Our study has limitations. First, the study design was retrospective, and the interval 
between the diagnostic process and the completion of the questionnaire differed significantly 
between patients. Therefore, some statements might be of uncertain reliability, as they 
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depend on the patients’ memory. Second, our questionnaire is not validated, but was merely 
created for the purpose of this study. Third, the significant decrement in diagnostic delay over 
the last years may be artificially distorted, because the maximal delay is always limited by the 
interval between the year of disease onset and the moment of study conduction, thus 
becomes linearly shorter with every year. Nevertheless, the fact that we observed a similar 
decrement also for the interval to the first medical consultation, which naturally is much 
shorter than the diagnostic delay and therefore less prone to such distortion, indicates that 
the observed reduction over time can be regarded as real.  
 In conclusion, delayed diagnosis of narcolepsy type 1 remains a major challenge, is 
highly common and associated with negative repercussions on many life aspects in affected 
patients. The accurate registration of all narcolepsy cases in specific databases and the 
establishment of distributed expert networks such as the European Narcolepsy Network are 
a first step in the right direction (Khatami et al., 2016). However, additional educational 
efforts and strategies are clearly mandatory, approaching not only the medical community 
but also the general population, perhaps by developing specific educational modules that can 
be implemented already at school level.   
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Table 1 Demographic, clinical, electrophysiological, genetic and neurochemical 
characteristics of the study population (n=52). Data are expressed as mean ± 
standard deviation. 
         
Female sex       27 (52%) 
Age at disease onset, y     22.1 ± 10.6 
Age at diagnosis, y      31.4 ± 15.0 
Diagnostic delay, y      8.9 ± 11.0 
Body mass index, kg/m2     26.1 ± 5.0 
Epworth Sleepiness Scale     16.3 ± 4.0 
Education  
- Primary school degree    13 (25%) 
- Secondary school degree    22 (43%) 
- College degree       5 (10%) 
- University degree     11 (22%) 
Work capacity at the moment of the study  
- Full       28 (54%) 
- Partial       18 (35%) 
- Incapacity to work       6 (11%) 
Narcolepsy symptoms at the moment of diagnosis, % 
- Excessive daytime sleepiness   100 
- Cataplexy       100 
- Sleep paralysis       52  
- Hypnagogic/hypnopompic hallucinations    48 
- Fragmented night-time sleep      69 
Pharmacological treatment at the moment of the study 
- Sodium oxybate     22 (42%) 
- Stimulants: modafinil / methylphenidate  21 (40%) / 7 (13%) 
- Antidepressants     12 (23%) 
MSLT findings (n=44) at the moment of diagnosis  
- Mean sleep latency, min    2.2 ± 1.6 
- Mean number of sleep onset REM periods  3.1 ± 1.0 
HLA-DQB1*06:02 positivity     42 of 42 tested patients (100%) 
Mean orexin level in cerebrospinal fluid, pg/ml  25 ± 41 (range: 0-163) 
- No lumbar puncture     13 (25%) 
- Undetectable CSF orexin levels   26 (50%) 
- Reduced CSF orexin levels    13 (25%) 
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Table 2 Aspects that characterize the patients’ troublesome journey towards the 
correct diagnosis of narcolepsy. Data are expressed as mean ± standard 
deviation (range). 
 
Time gap between disease onset and first medical consultation  3.2±5.1y (0-29y) 
The first doctor I visited was: 
- General practitioner       81% 
- Neurologist        9% 
- Other specialist       10% 
Which person motivated the first medical consultation? 
- Patient’s own initiative      56% 
- Advice by another person (family, friend, teacher)   44% 
Which symptom(s) urged the patient to seek medical help? 
- Excessive daytime sleepiness     71% 
- Cataplexy        48% 
- Hypnagogic/hypnopompic hallucinations    12% 
- Sleep paralysis       6% 
- Fragmented night-time sleep      25% 
Number of referred physicians before correct diagnosis   3.3±1.8 (0-10) 
Frequency of correct diagnosis at first medical consultation?  22% 
Which specialist made the correct diagnosis? 
- General practitioner       8% 
- Neurologist        82% 
- Psychiatrist        2% 
- Other specialist       8% 
Treatment prescriptions before correct diagnosis: 
- Vitamins        27% 
- Sleep extension       44% 
- Antidepressants       21% 
- Psychological support       21% 
- Iron replacement therapy      10% 
- Other         17%  
What is the cause of the diagnostic delay? 
- Insufficient knowledge on narcolepsy of treating physician  64% 
- Delay in seeking medical advice     24% 
- Combination of the above-mentioned causes   12%  
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FIGURE LEGENDS 
Figure 1 
The histogram (A) shows the distribution of diagnostic delays among 52 patients with 
narcolepsy type 1. Both the diagnostic delay (B) and the interval between disease onset and 
first medical consultation (C) have decreased over the last decades. Grey rectangles indicate 
patients with >1-year interval between onset of excessive daytime sleepiness and cataplexy. 
Figure 2 
Overview on several disease-related consequences, comparing the situations before and 
after diagnosis (i.e. at the moment of study conduction).  
Figure 3 
Before the correct diagnosis, patients received either no diagnosis at all or a wide variety of 
misdiagnoses.  
Figure 4 
Considerations of the narcolepsy patients about the diagnostic delay.  
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